Sundry Photography/iStock Editorial via Getty Images
- BioMarin Pharmaceutical (NASDAQ:BMRN), which is down ~25% since Sept. 1, said it is reaffirming its long-term financial guidance.
- This includes ~$4B in revenues in 2027; mid-teen CAGR through 2034; and potential treatments for skeletal conditions to become a more than $5B revenue opportunity.
- The outlook also sees a 40% non-GAAP operating margin starting in 2026 rising to the low- to mid-40% range; and more than $1.25B operating cash flow annually starting in 2027.
- Earlier in September, BioMarin unveiled a $500M cost transformation program.
More on BioMarin Pharmaceutical
- Ascendis Challenges BioMarin, But Market Response Seems Excessive
- BioMarin Pharmaceutical: A Volatile But Growing Trajectory
- BioMarin: Voxzogo Sales Surge Isn't Only Driving Force In 2024
- BioMarin off 17% as Ascendis data seen as threat to Voxzogo
- BioMarin plans $500M cost transformation to improve margins
